Kesimpta ofatumumab

First-dose systemic reaction severity is the single biggest conversion and adherence killer; patients who survive it with pre-medication and peer coaching become its strongest advocates.

• Convenience of monthly self-injection at home is the primary decision driver over Ocrevus/Briumvi, but the $7,000/month list price and co-pay volatility create an acute adherence-leak risk at insurance disruption moments.
• First-dose systemic reactions (fever, chills, transient leg weakness) are dramatically underplayed in HCP counseling; patients describe them as frightening and they drive a measurable proportion of early discontinuations.
• Recurrent upper respiratory and viral infections accumulate over months into a quality-of-life burden that pushes a subset of patients to unilateral discontinuation, often without contacting their neurologist first.
• Long-term users (2 plus years) who achieve no-evidence-of-disease-activity status become powerful organic advocates, framing Kesimpta as a near-invisible monthly routine with transformative disease control.